Literature DB >> 15453274

Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function.

S Singer1, S Rossi, S Verzosa, A Hashim, R Lonow, T Cooper, H Sershen, A Lajtha.   

Abstract

Nicotine, one of the most widespread drugs of abuse, has long been shown to impact areas of the brain involved in addiction and reward. Recent research, however, has begun to explore the positive effects that nicotine may have on learning and memory. The mechanisms by which nicotine interacts with areas of cognitive function are relatively unknown. Therefore, this paper is part of an ongoing study to evaluate regional effects of nicotine enhancement of cognitive function. Nicotine-induced changes in the levels of three neurotransmitters, dopamine (DA), serotonin (5-HT), norepinepherine (NE), their metabolites, homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindoleacetic acid (5-HIAA), and their precursor, L-DOPA, were evaluated in the ventral and dorsal hippocampus (VH and DH), prefrontal and medial temporal cortex (PFC and MTC), and the ventral tegmental area (VTA) using in vivo microdialysis in awake, freely moving, male Sprague-Dawley rats. The animals were treated with acute nicotine (0.5 mg/kg, s.c.) halfway through the 300-min experimental period. The reuptake blockers, desipramine (100 microM) and fluoxetine (30 microM), were given to increase the levels of NE and 5-HT so that they could be detected. Overall, a nicotine-induced DA increase was found in some areas, and this increase was potentiated by desipramine and fluoxetine. The two DA metabolites, HVA and DOPAC, increased in all the areas throughout the experiments, both with and without the inhibitors, indicating a rapid metabolism of the released DA. The increase in these metabolites was greater than the increase in DA. 5-HT was increased in the DH, MTC, and VTA in the presence of fluoxetine; its metabolite, 5-HIAA, was increased in the presence and absence of fluoxetine. Except in the VTA, NE levels increased to a similar extent with desipramine and fluoxetine. Overall, nicotine appeared to increase the release and turnover of these three neurotransmitters, which was indicated by significant increases in their metabolites. Furthermore, DA, and especially HVA and DOPAC, increased for the 150 min following nicotine administration; 5-HT and NE changes were shorter in duration. As gas chromatography experiments showed that nicotine levels in the brain decreased by 75% after 150 min, this may indicate that DA is more susceptible to lower levels of nicotine than 5-HT or NE. In conclusion, acute nicotine administration caused alterations in the levels of DA, 5-HT, and NE, and in the metabolism of DA and 5-HT, in brain areas that are involved in cognitive processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15453274     DOI: 10.1023/b:nere.0000035814.45494.15

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid.

Authors:  E Toth; H Sershen; A Hashim; E S Vizi; A Lajtha
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

Review 2.  Cognitive effects of nicotine.

Authors:  A H Rezvani; E D Levin
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

3.  5HT3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward.

Authors:  E Carboni; E Acquas; P Leone; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 4.  Nicotinic receptors in aging and dementia.

Authors:  Marina R Picciotto; Michele Zoli
Journal:  J Neurobiol       Date:  2002-12

5.  Individual variability of dopamine release from nucleus accumbens induced by nicotine.

Authors:  J H Johnson; C Zhao; J R James; J A Rosecrans
Journal:  Brain Res Bull       Date:  2000-02       Impact factor: 4.077

6.  Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats.

Authors:  M N Lipovac; A Hashim; H Sershen; D Allen; T Cooper; P Czobor; A Lajtha
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

7.  Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens.

Authors:  Istvan Sziráki; Henry Sershen; Audrey Hashim; Abel Lajtha
Journal:  Neurochem Res       Date:  2002-03       Impact factor: 3.996

8.  Simultaneous determination of norepinephrine, serotonin, and 5-hydroxyindole-3-acetic acid in microdialysis samples from rat brain by microbore column liquid chromatography with fluorescence detection following derivatization with benzylamine.

Authors:  Takashi Yoshitake; Kaoru Fujino; Jan Kehr; Junichi Ishida; Hitoshi Nohta; Masatoshi Yamaguchi
Journal:  Anal Biochem       Date:  2003-01-15       Impact factor: 3.365

9.  Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens of the mouse.

Authors:  Alessandro Zocchi; Elena Girlanda; Giorgia Varnier; Ilaria Sartori; Lara Zanetti; Grant A Wildish; Mark Lennon; Manolo Mugnaini; Christian A Heidbreder
Journal:  Synapse       Date:  2003-12-15       Impact factor: 2.562

10.  The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the alpha7-subunit-containing nicotinic acetylcholine receptor.

Authors:  Steven R Laviolette; Derek van der Kooy
Journal:  Psychopharmacology (Berl)       Date:  2003-02-05       Impact factor: 4.530

View more
  39 in total

1.  Nicotinic receptors in the dorsal and ventral hippocampus differentially modulate contextual fear conditioning.

Authors:  Justin W Kenney; Jonathan D Raybuck; Thomas J Gould
Journal:  Hippocampus       Date:  2012-01-23       Impact factor: 3.899

2.  Locally administered low nicotine-induced neurotransmitter changes in areas of cognitive function.

Authors:  E Shearman; S Rossi; H Sershen; A Hashim; A Lajtha
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

3.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

4.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

5.  Cigarette Smoking and Tryptophan Hydroxylase 2 mRNA in the Dorsal Raphe Nucleus in Suicides.

Authors:  Helene Bach; Victoria Arango; Suham A Kassir; Andrew J Dwork; J John Mann; Mark D Underwood
Journal:  Arch Suicide Res       Date:  2016-03-08

6.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

7.  Regional heterogeneity of nicotine effects on neurotransmitters in rat brains in vivo at low doses.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

8.  The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

Review 9.  Heterogeneity of reward mechanisms.

Authors:  A Lajtha; H Sershen
Journal:  Neurochem Res       Date:  2009-12-12       Impact factor: 3.996

Review 10.  Glial cells as therapeutic targets for smoking cessation.

Authors:  Mohit Kumar; Adewale Adeluyi; Erin L Anderson; Jill R Turner
Journal:  Neuropharmacology       Date:  2020-05-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.